Top Stocks Today : IIFL Securities has Buy call on Alembic Pharma

IIFL Securities has issued a "buy" recommendation for Alembic Pharma, with a target price of Rs 1225. This represents a potential upside of 3.4% from the current market price of Rs 1184.85. The recommendation is based on the company's strong fundamentals, including its presence in high-growth therapeutic areas and its commitment to research and development. Alembic Pharma is also expected to benefit from the increasing demand for generic drugs in both domestic and international markets.

About Alembic Pharma:

Alembic Pharmaceuticals Limited, listed on the National Stock Exchange (NSE) of India, is an integrated global pharmaceutical company with a presence in over 100 countries. Headquartered in Gujarat, India, Alembic Pharma manufactures and markets a wide range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and intermediates. Its product portfolio includes antibiotics, antifungals, cardiovascular drugs, gastrointestinal drugs, and over-the-counter (OTC) products. Alembic Pharma has a strong focus on research and development, with dedicated research centers in India and the United Kingdom. The company has a global footprint with manufacturing facilities in India, the United States, and Europe.

52 Week Price Trend:

Alembic Pharma, with a current market price (CMP) of Rs 1184.85, has witnessed a significant rise since its 52-week low of Rs 462.3. However, it remains below its 52-week high of Rs 1094. Alembic Pharma's stock performance is influenced by factors such as its financial results, industry trends, regulatory approvals, and macroeconomic conditions. Investors considering investing in the company should conduct thorough research and consult with financial advisors to make informed decisions based on their risk tolerance and investment goals.

Stratzy's MOST Analysis:

APLLTD has received a BB- rating under Stratzy's MOST framework, indicating medium fundamental risks. This rating is based on the company's management, outlook, safety, and trend, which are assessed individually and then combined to create an overall score. The BB- rating suggests that investors should be aware of potential risks associated with APLLTD before making investment decisions.

Company's Fundamentals:

Alembic Pharma (NSE: APLLTD) is a pharmaceutical company based in India. As of today, its stock price-to-earnings (PE) ratio is 34.88, implying that investors are willing to pay ₹34.88 for every ₹1 of earnings. Furthermore, the company's price-to-book (PB) ratio of 4.61 indicates that its market value is 4.61 times its book value, suggesting potential overvaluation. Despite this, Alembic Pharma offers a dividend yield of 0.76%, indicating a modest income potential for investors who hold its shares.

Fundamental and Technical information provided in this blog were last updated on 24 Jul, 2024

Disclaimer: The information and recommendations presented in this section, including any attached reports, are sourced from third-party providers through diverse channels. The views and opinions expressed within these materials belong solely to their respective creators. These views and opinions do not necessarily reflect the position of Stratzy Fintech Pvt Ltd. Stratzy explicitly disclaims any guarantees, express or implied, regarding the accuracy and reliability of the provided content. We strongly advise consulting with a licensed financial advisor before making any investment decisions based on this information. Remember, seeking independent financial advice is crucial.